Immunocore Holdings Plc Stock Price, News & Analysis

Immunocore Holdings Plc (Nasdaq: IMCR) announced presentations at key investor conferences in February 2023. The conferences include the Guggenheim Oncology Conference on February 8, SVB Securities Global Biopharma Conference on February 16, and Citi's 2023 Virtual Oncology Leadership Summit on February 22. Each session will feature a fireside chat and will be webcast live. Immunocore specializes in developing T cell receptor (TCR) bispecific immunotherapies for various diseases, including cancer and autoimmune conditions. The company’s flagship therapy, KIMMTRAK, is approved for treating certain types of uveal melanoma.

The report titled "Global TCR Therapy Market, 2022-2035" outlines significant growth prospects in TCR-based therapies, with an annual growth rate of 51% expected over the next decade. This emerging class of adoptive therapy targets specific tumor markers using genetically modified T-cells, showing efficacy primarily in hematological and solid tumors. The FDA's approval of Kimmtrak for treating metastatic uveal melanoma in January 2022 marks a milestone in the market. The market is projected to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma, with over 90% of therapy candidates being autologous.

The global cancer immunotherapy market is projected to reach USD 196.45 billion by 2030, growing at a CAGR of 7.2%, according to a report by Grand View Research. The increasing use of immunotherapy due to its targeted approach and heightened regulatory approvals for novel treatments are key growth factors. Monoclonal antibodies lead market share, while oncolytic viral therapies and vaccines are expected to grow rapidly. Lung cancer treatment is currently dominant, with a growing focus on prostate cancer. Notably, the Asia Pacific region is forecasted to experience the fastest growth driven by healthcare advancements and unmet medical needs.

Immunocore Holdings plc announced strategic priorities for 2023-2024, emphasizing pipeline expansion and the continued global rollout of KIMMTRAK (tebentafusp-tebn). The drug has been approved in over 30 countries with preliminary unaudited net sales of approximately $50 million for Q4 2022 and $140 million for the full year. Key priorities include the enrollment in IMC-F106C trials and the introduction of new ImmTAC candidates targeting PRAME and PIWIL1. The company aims to solidify KIMMTRAK as the first-line treatment for metastatic uveal melanoma.

Immunocore Holdings (Nasdaq: IMCR) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 a.m. PST. The company's management will engage in a fireside chat, which will be webcast live, and available on Immunocore's website. Immunocore specializes in pioneering T cell receptor bispecific immunotherapies, notably its approved oncology therapeutic, KIMMTRAK, intended for treating unresectable or metastatic uveal melanoma. The company is progressing on multiple clinical and pre-clinical programs across various disease areas.

Immunocore has won the Prix Galien France 2022 award in the ‘Medicine in Innovative Therapeutics’ category for its treatment KIMMTRAK (tebentafusp), the world’s first T cell receptor therapy for unresectable or metastatic uveal melanoma. Approved by the FDA and several health authorities in 2022, KIMMTRAK targets a rare and aggressive eye cancer that previously lacked specific treatments. This honor reflects both the therapy's impact on patients and the innovative technology developed by Immunocore, marking a successful year for the company.

Immunocore presented data for its bispecific T cell engager IMC-C103C targeting MAGE-A4 in ovarian cancer. The Phase 1 trial involved 33 heavily pre-treated patients. Results showed a manageable safety profile and some clinical activity, although the RECIST response rate was low among patients with low MAGE-A4 expression. Notably, reductions in ctDNA were observed even in patients with minimal MAGE-A4 expression. IMC-C103C is being co-developed with Genentech.

Immunocore Holdings plc (Nasdaq: IMCR) and Gadeta B.V. have entered a collaboration to develop the first gamma delta TCR ImmTAC® for treating solid tumors, including colorectal cancer. This partnership marries Gadeta's expertise in gamma delta TCRs with Immunocore's TCR bispecific engineering. Immunocore has an option for exclusive licensing of ImmTAC candidates resulting from this collaboration, and Gadeta is set to receive upfront fees and milestone payments. The new gamma delta TCRs exemplify a promising solution for patients without HLA restrictions.

Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in the 5th Annual Evercore ISI HealthCONx Conference scheduled for November 30, 2022, at 8:25 a.m. ET. The management will engage in a fireside chat, which will be available for live streaming and later as a replay on Immunocore's website.

Immunocore specializes in T cell receptor bispecific immunotherapies aimed at treating various diseases, including cancer and autoimmune disorders. Their lead product, KIMMTRAK, is approved for patients with metastatic uveal melanoma.